Currently out of the existing stock ratings of Kevin Degeeter, 108 are a BUY (93.1%), 7 are a HOLD (6.03%), 1 are a SELL (0.86%).

Kevin Degeeter

Work Performance Price Targets & Ratings Chart

Analyst Kevin Degeeter works at OPPENHEIMER with a stock forecast success ratio of 44.35% fulfilled within 133.67 days on average. Previously, Kevin Degeeter worked at LADENBURG.

Kevin Degeeter’s has documented 208 price targets and ratings displayed on 30 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ORTX, Orchard Therapeutics PLC at 13-Jun-2023.

Wall Street Analyst Kevin Degeeter

Analyst best performing recommendations are on DMTK (DERMTECH).
The best stock recommendation documented was for NVTA (INVITAE CORP) at 1/12/2021. The price target of $51 was fulfilled within 1 day with a profit of $3.41 (7.17%) receiving and performance score of 71.65.

Average potential price target upside

BNGO Bionano Genomics CYCC Cyclacel Pharmaceuticals DMTK DermTech EXAS EXACT Sciences FLGT Fulgent Genetics HGEN Humanigen INFI Infinity Pharmaceuticals IONS Ionis Pharmaceuticals MTEM Molecular Templates NVAX Novavax NVCR Novocure Ltd NVTA Invitae Corp OPK Opko Health ORIC Oric Pharmaceuticals  ORTX Orchard Therapeutics PLC PRTG Portage Biotech PSNL Personalis PTE Polarityte SNSE Sensei Biotherapeutics SPRO Spero Therapeutics VCEL Vericel Corp Ord ANTX AN2 Therapeutics CBIO Catalyst Biosciences CDTX Cidara Therapeutics IDYA Ideaya Biosciences KIN Kindred Biosciences MBRX Moleculin Biotech MDXH MDxHealth SA ADR SERA Sera Prognostics GHDX Genomic Health

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

30

3 months 15 days ago

2/3 (66.67%)

$22.52 (301.07%)

367

Buy

9

$7.7 (592.31%)

3

6 months 17 days ago

1/4 (25%)

$5.01 (125.56%)

157

Buy

2

$0.7 (53.85%)

35

6 months 18 days ago

1/2 (50%)

$-2.01 (-50.12%)

69

Buy

80

1 years 1 months 23 days ago

2/3 (66.67%)

$58.3 (268.66%)

204

Buy

1 years 7 months 10 days ago

2/3 (66.67%)

$64.6 (85.68%)

137

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Kevin Degeeter?

On 2011

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?